Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025817 | 0.95 | MAPT (0.55) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL30932049 | 0.89 | MAPT (0.53) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL31276701 | 0.88 | USP30 (0.49) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL19297555 | 0.88 | GPR119 (0.55) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL23539023 | 0.88 | CYP3A4 (0.48) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL23538631 | 0.88 | USP30 (0.46) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL521045 | 0.86 | GPR119 (0.51) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL29384737 | 0.86 | GPR119 (0.51) | MAPTLMNAALDH1A1GPR119USP30 | |
| SCHEMBL19495864 | 0.86 | MAPT (0.55) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL21876693 | 0.86 | USP30 (0.46) | MAPTLMNAALDH1A1GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| CN-113024516-B | Double-target PARP/EZH2 inhibitor, preparation method and application | 中国药科大学 | 2022-05-17 | — | — | CN | claimed |
| EP-4200297-B1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4200015-B1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORP (US) | 2026-04-23 | — | — | US | disclosed |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007065664-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | disclosed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | disclosed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | MAPT 4555/4885LMNA 4019/4885ALDH1A1 2085/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | MAPT 1585/4885LMNA 4398/4885ALDH1A1 700/4885 |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | CTSB, CTSK, CTSS | MAPT 3972/4885LMNA 819/4885ALDH1A1 3183/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | MAPT 4019/4885LMNA 756/4885ALDH1A1 1145/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | MAPT 4748/4885LMNA 1046/4885ALDH1A1 2050/4885 |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | PSME2, MKRN3, RPS6KA2 | MAPT 2763/4885LMNA 4171/4885ALDH1A1 3760/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | MAPT 3834/4885LMNA 1254/4885ALDH1A1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.